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Cranial lymphatic vessels (LVs) are involved in the transport of ﬂuids, macromolecules and
central nervous system (CNS) immune responses. Little information about spinal LVs is
available, because these delicate structures are embedded within vertebral tissues and dif-
ﬁcult to visualize using traditional histology. Here we show an extended vertebral column LV
network using three-dimensional imaging of decalciﬁed iDISCO+-clariﬁed spine segments.
Vertebral LVs connect to peripheral sensory and sympathetic ganglia and form metameric
vertebral circuits connecting to lymph nodes and the thoracic duct. They drain the epidural
space and the dura mater around the spinal cord and associate with leukocytes. Vertebral
LVs remodel extensively after spinal cord injury and VEGF-C-induced vertebral lym-
phangiogenesis exacerbates the inﬂammatory responses, T cell inﬁltration and demyelination
following focal spinal cord lesion. Therefore, vertebral LVs add to skull meningeal LVs as
gatekeepers of CNS immunity and may be potential targets to improve the maintenance and
repair of spinal tissues.
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The lymphatic vasculature controls ﬂuid homeostasis,macromolecular clearance, and immune responses inperipheral tissues1,2. The brain was long considered to lack
lymphatic vasculature, which has raised questions about how the
cerebral interstitial ﬂuid is cleared of waste products3,4 and how
immune surveillance of the brain is maintained5–7. This ﬂuid is
formed by water and small solutes that are exchanged through the
capillary walls between the blood vessels and the brain. It has a
similar composition to the cerebrospinal ﬂuid (CSF) which drains
the brain ventricles and meninges and is mainly produced in the
choroid plexus8. The CSF has been proposed to dynamically
exchange with interstitial ﬂuid along glial lymphatic (glymphatic)
non-vascular periarterial routes, without crossing the endothelial
cell layer, and subsequently to be cleared from the brain into the
subarachnoid space via similar perivenous routes6,9. The CSF
outﬂow system involves speciﬁc extracranial lymphatic vascu-
lature beds10,11. The recent identiﬁcation of cranial meningeal
LVs (mLVs) established another pathway for CSF outﬂow into
deep cervical lymph nodes (dcLNs)12–15. In mice, cranial mLVs
are mainly aligned alongside large dural venous sinuses, menin-
geal arteries and cranial nerves. Along the sagittal suture, the
cranial lymphatic vasculature is valveless with small-diameter
LVs, while it forms a larger network with valves and capillaries
located adjacent to the subarachnoid space toward the basal
aspects of the skull12–16. Cranial mLVs in the basal parts of the
skull were initially shown to transport ﬂuorescent tracers toward
dcLNs via foramina at the base of the skull12. The basal mLVs
include capillaries located adjacent to the subarachnoid space that
have button-like junctions, allowing CSF uptake for the clearance
of CSF macromolecules15. Using multiphoton microscopy, mac-
romolecule and cell transport was reported also in mLVs along-
side the superior sagittal and transverse sinuses17, and consistent
results were obtained by MRI imaging of primate and human
mLs16. Meningeal lymphatic vasculature also exists in the skull
of primates, including common marmoset monkeys and
humans14,16.
VEGF-C expression in vascular smooth muscle cells and
VEGFR3 in lymphatic endothelial cells (LECs) are essential for
the development of cranial mLVs14,18. The meningeal lymphatic
vasculature develops later than the rest of the lymphatic network,
ﬁrst appearing at birth in the basal parts of the skull, then
expanding during the neonatal period along dural blood vessels
whose vascular smooth muscle cells supply the VEGF-C14.
Immuno-histology on whole-mount preparations or cryosections
showed that, during the ﬁrst weeks after birth, LVs also developed
a large network closely attached to the vertebral column14. These
vertebral lymphatic vessels (vLVs) occur mainly in intervertebral
spaces, having different morphology ventrally and dorsally, as
well as along spinal nerve rami when exciting the spinal canal.
Cranial mLVs located dorsally around the cisterna magna and
ventrally around the foramen magnum appeared to be connected
to vertebral LVs14. Further characterization conﬁrmed that lym-
phatic vasculature extended caudally into into the whole vertebral
canal and connected from there to the peripheral lymphatic
vessels, as proposed by seminal papers19,20. We wanted to pro-
duce a three-dimensional (3D)-map of the vertebral lymphatic
system that respects structural interactions between the spinal
cord and meninges, the surrounding bone and mesenchymal
environment and the neighboring peripheral nervous system
(PNS). This required us to preserve the overall bone structures
around the CNS while simultaneously accessing and labeling the
LVs of meninges contained within the protective layers of mus-
cular and skeletal tissues. To do so, we used the iDISCO+ tech-
nique, which enables volume imaging of immunolabeled
structures in complex tissues21,22. Imaging of iDISCO+ treated
vertebral segments with a light-sheet ﬂuorescent microscope
(LSFM) revealed an extensive lymphatic vasculature inside the
vertebral canal.
Here, we report that vertebral lymphatics are predominantly
localized in the epidural space above the dura mater and drain
tracers injected into the thoraco-lumbar spinal cord toward
thoracic mediastinal lymph nodes. In addition, we show that
VEGF-C-induced vertebral lymphangiogenesis exacerbates
immune-cell inﬁltration and cytotoxic demyelination of spinal
cord lesions in the lysolecithin (LPC)-induced focal demyelina-
tion model21. In the CNS, photoablation of the skull meningeal
lymphatic vasculature has been reported to reduce the inﬂam-
matory response of brain-reactive T cells around demyelinated
lesions in the EAE (experimental autoimmune encephalomyelitis)
model of multiple sclerosis22. Therefore, the vertebral lymphatic
system conveys an additional remote control of immune sur-
veillance to the CNS.
Results
Lymphatic vasculature pattern in the thoracic spine. To label
vascular, immune and neural cell compartments within the intact
vertebral column, segments of 2–4 vertebrae were dissected
together with the surrounding muscle tissue and decalciﬁed in
Morse’s solution23. iDISCO+ tissue clearing and immunolabel-
ing followed by light-sheet ﬂuorescence microscope (LSFM)
imaging were then used for 3D-reconstruction of the spinal LV
network.
The iDISCO+ protocol was ﬁrst applied to the thoracic spine,
with the goal to characterize the 3D anatomy of vLVs. Figure 1a,
b illustrates a lateral view of Alizarin red staining of bones within
a cleared spinal column segment to reveal the vertebrae,
intervertebral spaces and ligamentum ﬂavum. Figure 1c shows
a schematic latero-frontal perspective view of a thoracic vertebral
segment. Lymphatic endothelial cells (LECs) were labeled using
polyclonal antibodies against two well-established LEC markers,
the LYVE1 cell surface receptor and the nuclear PROX1
transcription factor24–26. PROX1-labeled LYVE1-positive LECs
and LYVE1-negative cells within the spinal cord that were
previously identiﬁed as oligodendroglial cells27 (Supplementary
Fig. 1a, b). LYVE1 labeled PROX1-positive LECs and PROX1-
negative myeloid cells, as previously reported27 (Supplementary
Fig. 1a, b). LYVE1-positive LECs within the vertebral column
were negative for the blood vessel marker Podocalyxin28 in the
present conditions of immunolabeling (Supplementary
Fig. 1c–h).
Despite labeling of some non-LECs, both markers clearly
revealed a dense lymphatic network that was present between
vertebrae and appeared mainly conﬁned to the intervertebral
spaces (Fig. 1d, e and Supplementary Movies 1, 2)14. A few
longitudinal vessels linked adjacent intervertebral lymphatic
circuits together along the spinal cord (salmon arrows in Fig. 1e,
f). Vertebral LVs (vLVs) were also connected to the peripheral
lymphatic system surrounding the vertebrae, dorsally through the
ligamentum ﬂavum (Fig. 1f), dorsolaterally along the dorsal facet
joint and ventrolaterally through the intervertebral foramen along
ventral nerve rami (Fig. 1e, f).
We next used Imaris-3D software to illustrate the anatomy of
vLV circuits. We used global image acquisitions of the thoracic
spine (see Supplementary Movie 2), showing a succession of
vertebral lymphatic units along the rostro-caudal axis. Images
were then segmented to generate a color-coded map of vLV
circuits. In Fig. 1g, h and Supplementary Movies 3, 4, each color
deﬁnes the PROX1+ pattern of one vertebra along three
successive thoracic vertebrae (red, blue, green) as well as the
peripheral lymphatic vasculature (white). This conﬁrms a
metameric organization of vLVs14.
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Modular architecture of vertebral lymphatic vasculature. We
next mapped the vLV network in the vertebral canal from the
dorsal to the ventral part of a vertebra. Supplementary Movie 2
and the corresponding view in Fig. 2a, b show vLVs around one
segment of the thoracic spinal cord, and areas where higher
magniﬁcation views were taken. Dorsally, semicircular lymphatic
vessels navigate around the spinal cord (Fig. 2c). At the ventral
border of the ligamentum ﬂavum, located at the dorsal midline
between two spinous processes, these vLVs contact lymphatic
branches entering the epidural space from the overlying dense
peripheral lymphatic vasculature (Fig. 2d). Laterally, at the level
of the transverse facet joints, semicircular vessels including per-
ipheral lymphatic vessels from the dorsal plexus converge toward
a lymphatic circle (blue arrow in Fig. 2c). From this point, vLVs
distribute either radially toward the periphery, or ventrally toward
the emergence of the dorsal spinal nerve roots (red double arrow
in Fig. 2c). Supplementary Movie 2 allows to follow peripheral
lymphatic vessels from the dorsal midline of intervertebral liga-
ments to the lateral exit points of the vertebral canal. At the
intervertebral foramen, DRGs are covered by vLVs that converge
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Fig. 1 Segmental pattern of the vertebral lymphatic vasculature in the thoracic spine. a Alcian blue/Alizarin red staining of the mouse vertebral column with
boxes indicating position of images shown in Figs. 1–4 (thoracic vertebrae) and 5 (cervical and lumbar vertebrae), spatial orientation (A: anterior, P:
posterior, L: lateral, V: ventral). b Alizarin red staining of two successive thoracic vertebrae (delimited by red/blue dots, lateral view). LF: ligamentum
ﬂavum, red asterisk: ventral vertebral body, blue arrow: facet joint (FJ), red arrowhead: ventral intervertebral disk, blue asterisk: intervertebral foramen.
c latero-frontal schematic drawing corresponding to (b). DM: dura mater, LM: leptomeninges (pia mater and arachnoid), SC: spinal cord, SN: spinal nerve.
d Dorsal view of LYVE1 staining. Red and blue areas correspond to two successive vertebrae. Note LVs lining ligamentum ﬂavum. e, f Dorsal (e) and lateral
(f) views of the PROX1 expression pattern. Red and blue areas correspond to two successive vertebrae. Salmon arrows: intervertebral LVs, blue arrow:
dorsal LVs. g, h Segmented images of the PROX1 LV network (fronto-dorsal (g) and lateral (h) views) highlighting three successive vertebral LV units (red,
blue, green). Scale bars: 2 mm (a); 300 µm (b, e, f); 200 µm (d, g, h)
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Fig. 2 Modular architecture of vertebral lymphatic vasculature. a Frontal view of a cleared thoracic vertebra stained with an anti-PROX1 antibody. Red
asterisk: vertebral ventral body, SC: spinal cord spatial orientation (D: dorsal, L: lateral, V: ventral). b Magniﬁcations of red boxed areas are shown in (c–g).
c Semicircular dorsal LVs (red arrow) surround the spinal cord, exit dorsolaterally (blue arrow) and also extend a latero-ventral connection to the dorsal
nerve root (double red arrows in (c) and (e)). Note PROX1+ cells in SC and perivertebral muscles (M), FJ: facet joint. d At the ventral face of the
ligamentum ﬂavum (LF) located between two spinous processes, dorsal LVs (blue arrows) enter the vertebral canal and join semicircular LVs (red arrows).
Note circles of LVs bordering the upper side of the epidural space (ES). e Ventrolateral LV circuitry around DRG (red arrowheads). Blue dotted-lines: spinal
nerve roots, red dotted-lines: DRG. f Lateral view with intervertebral LVs (salmon arrows). g Two ventral branches (red arrows and arrowheads) run
between each side of the ventral midline (VM) and the DRG. h Schematic representation of a frontal view of a thoracic vertebral LV unit. Longitudinal
connecting vessels between vertebral units are not represented. FJ: facet joint; LF: ligamentum ﬂavum; ES: epidural space; DRG: dorsal root ganglia; VM:
ventral midline; SC: spinal cord. Black letters refer to images in (c–g). Scale bars: 300 µm (a–g)
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from the ventral and dorsolateral circuits at their proximal and
distal end, respectively (arrowheads in Fig. 2e). In addition to
these two circuits, a few longitudinal connecting vessels link
vertebral lymphatic units together (Fig. 2f). Ventrally, a second
circuit of semicircular lymphatic vessels converges toward the
ventral spinal nerve rami exit, while no lymphatic vessels are
observed at the ventral midline (Fig. 2g)14. We observed a similar
vLV pattern in other thoracic segments (n= 5) allowing us to
generate a schematic representation of the different compart-
ments of the vLV circuitry with a speciﬁc color code for the
intervertebral circuits (red) and vertebral branches of the per-
ipheral LV (blue) (Fig. 2h).
To verify that the iDISCO+ protocol preserved the integrity of
tissue structure and anatomy29, we performed additional
immunostainings on decalciﬁed EDTA-treated vertebral seg-
ments that were either cryoprotected and frozen, or dehydrated
and embedded in parafﬁn. Confocal and conventional micro-
scopy imaging of sections perfectly reproduced the 3D-images
collected with a LSFM on IDISCO+ treated samples (Supple-
mentary Fig. 2) and thus substantiated the iDISCO+ based-model
described above.
Vertebral lymphatic vessels contact sympathetic ganglia. vLVs
covering the dura mater of DRGs (Fig. 2e) extend collateral
branches bilaterally along the spine, which contact paravertebral
PROX1low ganglia (Fig. 3a, b). PROX1 is known to be expressed
in the sympathetic neuronal lineage30 and double labeling with
antibodies against PROX1 and tyrosine hydroxylase (TH), a
speciﬁc marker of adrenergic nerves and ganglia, conﬁrmed that
speciﬁc branches emerging from vLVs connected to TH+/
PROX1low sympathetic ganglia (Fig. 3c). On each side of the
spinal cord, PROX1+/LYVE1+ LVs contacted one sympathetic
ganglion per spinal level (Fig. 3d–f). Complementary analyses by
high resolution confocal imaging on vertebral column cryosec-
tions showed that the connection between LVs and sympathetic
ganglia (Fig. 3g, h) occured at the surface of the ganglion cortical
layer (Fig. 3i). These data reveal a hitherto unknown anatomical
interaction between the autonomous nervous system and lym-
phatic vessels derived from vLVs.
vLV patterning differs between vertebral column levels. We
next examined the lymphatic vasculature at the cervical and
thoracic level of the vertebral column. Stereomicroscopic imaging
of whole-mount preparations revealed LVs around the cisterna
magna and within the vertebral canal, where they located at the
level of intervertebral ligaments and surrounding spinal nerve
rami (Supplementary Fig. 3a–d). The LV patterning in cervical
vertebrae and along the vertebral column was then analyzed in
further detail by volume imaging.
In the cervical region, we observed a dorsal extravertebral
lymphatic plexus (blue arrow, Fig. 4a) as well as intravertebral
vLVs that exited ventrally and bilaterally (red arrows) through the
intervertebral foramen to ventrally (salmon arrow) connect to
dcLNs (green in Fig. 4b; Supplementary Fig. 3e, f). Thoracic vLVs
were deﬁned by a large dorsal extravertebral plexus (blue arrow,
Fig. 4c) and a direct connection from ventrolateral DRG LVs (red
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Fig. 3 Vertebral lymphatic vessel connections with sympathetic ganglia. a, b Thoracic PROX1+ LVs contact paravertebral sympathetic ganglia (SG) (blue
arrows). White dotted-lines: DRG. c PROX1 (white) and tyrosine hydroxylase (TH, red) double labeling shows a ventral LV branch contacting a
paravertebral TH+ sympathetic ganglion (blue arrow). d–f PROX1 (white)/LYVE1 (red) double labeling of the LV-SG connection (blue arrow). g–i 2D-
confocal images of cervical cryosections labeled with LYVE1 (white), TH (red), and DAPI (blue). White box: area magniﬁed in (h) and (i). A LV contacts a
TH+ SG (blue arrow). Note a second ventral LV branch running along the SG, without entering its cortical layer (h, salmon arrow). This branch is also seen
in panel (b) (salmon arrow). White dotted-lines: DRG; Red asterisk: vertebral ventral body; SC: spinal cord. Scale bars: 100 µm (a–h); 200 µm (i)
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arrow) to the thoracic lymphatic duct (green in Fig. 4d). The
thoracic and lumbar regions displayed similar extensions and
patterns of extravertebral and intravertebral LVs (Fig. 4c, e). In
lumbar vertebrae, the ventrolateral circuits that exited on each
side of the vertebral canal connected to lymph nodes. As shown
in green in Fig. 4f, lymphatic vessels circumvented the ventral
body of the lumbar vertebra (salmon arrow), converged on the
ventral midline and split into two branches running toward the
pair of renal lymph nodes. Therefore, the vLV architecture is
conserved along the vertebral column, but the extension of
extravertebral and intravertebral vessels around the spinal cord
and their connection to the peripheral lymphatic system differs
between the cervical, thoracic and lumbar vertebral levels.
Epidural and dural vertebral lymphatic vessels. To obtain a 3D
annotation of vLV localization in the spinal canal and meninges,
PROX1-labeled vertebral volumetric images were used to gen-
erate segmented images of membranes and the epidural space
around the spinal cord. We manually annotated in 3D the
meninges, the epidural space and ligamentum ﬂavum (Fig. 5a).
Figure 5a shows one image slice with a color code for meningeal
layers (purple area) and the epidural space (green area). We also
present color-coded layer masks for the arachnoid and dura
mater together (purple area in Fig. 5b), or the dura mater and the
epidural space together (green area in Fig. 5c). The overlay of
both masks revealed that PROX1+ vLVs mainly localized in the
epidural space (green), while the underlying dura mater layer
(gray) includes ventral vLVs (white) around DRGs (Fig. 5d and
Supplementary Movie 5). As shown on a lateral view (Fig. 5e),
dura mater vLVs localized most extensively at bilateral DRGs.
Interestingly, connecting vessels between two successive verteb-
rae (salmon arrows in Fig. 5e) navigated in the epidural space
and appeared to join vLVs of the dura mater close to the DRGs
(white arrows in Fig. 5e), suggesting a possible conﬂuence of
peripheral lymph and CSF at this level. Scheme representing the
anatomy of vLVs in the thoracic vertebral canal is shown in
Fig. 5f.
Complementary examination of whole-mounted spinal cord
meninges (Supplementary Fig. 4a) and cryo/parafﬁn sections
(Supplementary Fig. 4b–g) conﬁrmed that the dura mater
lymphatic vessels were restricted around the DRGs and spinal
nerve rami and located on the dorsal surface of the dura mater
(Supplementary Fig. 4c, f), which is not in direct contact with
the CSF.
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Fig. 4 Variations of vLV pattern along the vertebral column. a–f Pattern of PROX1+ LVs in the cervical (a, b), thoracic (c, d), and lumbar (e, f) vertebral
column, spatial orientation (D: dorsal, L: lateral, V: ventral). Left panels show frontal views, right panels show connection to peripheral lymph nodes (LN)
and thoracic duct (TD). a, c, e Note fewer LVs in the dorsal plexus between intervertebral spinous processes of cervical and lumbar vertebrae compared to
thoracic ones (blue arrows). a LVs exit bilaterally (red arrows) through the intervertebral foramen. a, c, e Also note differences in ventral root exit circuits
between regions (salmon arrows). b, d, f LV ventral exit circuits (green) to b deep cervical LNs, d thoracic duct, or f to renal LNs. Red asterisk: vertebral
ventral body; SC: spinal cord; Ao: Aorta. Scale bars: 300 µm (a–f)
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vLV-mediated drainage of the vertebral column. The function
of the vLV system was explored by testing the drainage potential
of epidural and dura mater vLVs. Molecular tracers were injected
into one side of the spinal cord parenchyme at the thoraco-
lumbar level, and their distribution around the injection site was
examined 15 and 45 min after injection (a.i.) (Fig. 6a). We used as
molecular tracers either LYVE1 antibodies that were detected
with a secondary antibody, or ﬂuorescent albumin (OVA-A555).
It is worth noting that this surgery procedure punctures the dura
mater, which allows access of injected tracer into the epidural
space located above spinal meninges, locally at the puncture site.
LSFM imaging of iDISCO+-treated vertebral samples revealed
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Fig. 5 Epidural and dural lymphatic circuits of the spine. a 2D-single frontal image slice (2 µm thick) of the cervical vertebral column with enhanced
brightness to reveal PROX1-expressing nuclei and spinal cord (SC), meninges including pia mater (Pi), arachnoid (A) and dura mater (DM), the epidural
space (ES), and the ligamentum ﬂavum (LF). A color-coded segmentation of layers around the spinal cord shows the meningeal layers in purple and the
dura mater plus the epidural space in green. b–d 3D-reconstruction of frontal images of the cervical vertebral column with color-coded layers: the
arachnoid and dura mater in purple (b); the dura mater and epidural space in green (c); combined layer marks showing the arachnoid in purple, the dura
mater in white, and the epidural space in green (d), spatial orientation (D: dorsal, L: lateral, V: ventral). A noticeable LV network ﬁlls the epidural space
(green) while dura mater LVs (white) are mainly restricted to DRGs (white arrows) and few branches on each side of the dorsal and ventral midline. e 3D-
reconstruction of lateral images of the thoracic vertebral column with color-coded layers illustrated in (d). Blue dotted-lines: bilateral DRGs; salmon arrows:
intervertebral LVs; Red asterisk: vertebral ventral body. Vx: vertebra x, Vx+ 1: vertebra x+ 1. f Schematic representation of the lymphatic vasculature in the
thoracic vertebral column. LVs are present in the epidural space (green) around the spinal cord and in the dura mater (purple). Extravertebral LVs extend
dorsal processes (blue) and ventral connections with sympathetic ganglia (SG, deep blue) and the thoracic duct (TD, light blue). Blue arrowheads; exit
points of vertebral lymphatic circuits; Blue dots: connections with extravertebral lymphatic networks; Black asterisk: vertebral ventral body; DRG: dorsal
root ganglia; FJ: facet joint; LF: ligamentum ﬂavum; SC: spinal cord; SG: sympathetic ganglia. Scale bars: 300 µm (a–e)
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extravertebral LVs and lymph node (blue). Blue dots: accumulation of OVA-A555 tracer in LVs and lymph node. MeLN: mediastinal lymph node; PvLV:
paravertebral lymphatic vessel. Scale bars: 200 µm (b–e); 1 mm (f)
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that the injected markers localized in and around PROX1+ vLVs
of the epidural space and dura mater (white arrows, Fig. 6b–e and
Supplementary Movie 6). Confocal imaging of decalciﬁed and
frozen samples showed that OVA-A555 localized within the vLV
lumen (Supplementary Fig. 5), thus demonstrating the uptake
and drainage properties of vLVs.
15 min after OVA-A555 injections into the thoraco-lumbar
spinal cord, tracer accumulated in the ipsilateral paravertebral
lymphatic vessel and mediastinal lymph node, in 9 out of 12 cases
(Fig. 6f). Therefore, vLVs provide a regional outﬂow for epidural
ﬂuids toward lymph nodes. A schematic model of the thoraco-
lumbar lymphatic drainage circuitry is shown in Fig. 6g.
Vertebral LVs respond to VEGF-C and spinal cord injury. To
assess the dependence of vLVs on VEGF-C, we generated gain-of-
VEGF-C signaling mice by either intra-cisterna magna (i.c.m.) or
lumbo-sacral (l.s.) injection of adeno-associated viral vectors
(AAVs) encoding mVEGF-C (AAV-mVEGF-C)15 (Fig. 7a, d).
Control mice were injected with AAVs encoding soluble
mVEGFR34–7-Ig (VEGFR3 ectodomains that do not bind VEGF-
C) (AAV-control)31. One month later, mice were analyzed by
PROX1 immunostaining. Compared to controls, VEGF-C injec-
ted mice showed a strongly expanded vLV network, in particular
of dorsolateral lymphatic rings in the intervertebral disk of cer-
vical vertebrae after i.c.m. injection (Fig. 7b, c and Supplementary
Movie 7), and lumbar vertebrae after l.s. injection (Fig. 7e, f).
To determine if adult vLVs might respond to spinal cord
injury, we injected LPC (1μl) into one side of the spinal cord at
the thoraco-lumbar level (Fig. 7g). LPC is toxic to oligoden-
drocytes and rapidly induces demyelinating spinal cord lesions
(Fig. 7i inset)32,33. Within a week after the surgery, a robust
extravertebral and intravertebral growth in LVs was induced in
LPC-injured mice (Fig. 7h–i and Supplementary Movie 8). To
quantify the response, we opened the vertebral column to expose
intravertebral vLVs that were stained with LYVE1 on whole-
mount preparations, followed by vessels diameter and surface
area measurements (as red stippled area in Fig. 7i). Pairwise
Mann–Whitney U test comparison to control mice revealed a
signiﬁcant increase in vLV area after LPC injury (p= 0.0286),
however, this did not reach statistical signiﬁcance in a mutliple
group comparison (Supplementary Fig. 6e). LPC-lymphatic vessel
diameter and area were not affected by control AAV-
mVEGFR34–7-Ig (LPCcontrol), while they were signiﬁcantly
enhanced in mice pretreated with AAV-mVEGF-C (LPCVEGF-C
mice) for one month (Fig. 7j, Supplementary Fig. 6e). LPC injury
in mice pretreated by lumbo-sacral (l.s.) injection of AAVs
encoding soluble mVEGFR31–3-Ig (LPCVEGF-C trap mice) for one
month resulted in reduction of vLV diameter that was
signiﬁcantly different from LPCcontrol mice (Fig. 7j). LPCVEGF-C
trap mice showed a reduction of vLV area that was signiﬁcantly
different from LPCcontrol mice in a pairwise Mann–Whitney U-
test comparison (p= 0.0286), but failed to reach statistical
signiﬁcance in a multiple group comparison (Supplementary
Fig. 6e). However, LPC injury in K14-VEGFR3-Ig homozygous
mice, in which endogenous VEGF-C/VEGF-D ligands are
constitutively trapped to prevent VEGFR3 signaling31, was
associated with a signiﬁcant reduction of vLV diameter and area
compared to heterozygous littermates (Fig. 7k, Supplementary
Fig. 6f). Taken together, these data show that vLVs respond to
VEGF-C and spinal cord injury.
Effects of vLVs on myeloid and lymphoid cells. We next asked
whether vLVs concentrated myeloid and lymphoid cells, as pre-
viously reported for skull lymphatics13. Pre-cleared segments of
the vertebral column co-labeled with antibodies against LYVE1
and the common leukocyte antigen CD45 showed that CD45+
leukocytes inside the vertebral canal were concentrated around
LYVE1+ vLVs (Fig. 8a–d). On cryosections we observed leuko-
cytes concentrated close to, or within, Vegfr3:YFP+ lymphatic
vessels in intervertebral ligaments (Fig. 8e). CD45+ leukocytes
included around 40% of C11b+ macrophages, 40% of CD3+
T cells, and 20% of CD19+ B cells. Furthermore, around 40% of
CD45+ leukocytes expressed MHCII (Supplementary Fig. 6a–d).
Leukocyte numbers and ratios were similar between control,
AAV-mVEGF-C and K14-VEGFR3-Ig homozygous and hetero-
zygous mice (Supplementary Fig. 6a–d). In contrast, LPC injury
induced a strong increase in leukocyte numbers around vLVs that
was further enhanced by AAV-mVEGF-C and reduced by
mVEGF-C trap (Fig. 8f).
The size of demyelinated lesions, identiﬁed as spinal white
mater areas devoid of MBP (Myelin Basic Protein) expression,
was signiﬁcantly increased in LPCVEGF-C mice compared to
control AAV treated mice (Fig. 8g, h). LPCVEGF-C trap mice mice
showed a signiﬁcantly reduced lesion size when compared to
LPCVEGF-C mice, and a slight but not signiﬁcant reduction in
lesion area when compared to LPCcontrol mice (Fig. 8g, h).
Further quantiﬁcations were done on spinal cord sections in
the lesioned area vs. the contralateral uninjured side. As expected,
LPC injection reduced the number of NeuN-positive neurons in
the peri-lesional area compared to the uninjured side (Supple-
mentary Fig. 7a). Pre-treatment with AAV-control or with AAV-
mVEGF-C trap had no effect compared to LPC injury alone,
while AAV-mVEGF-C further reduced the number of NeuN-
positive neurons on the injured side, indicating deleterious effects
of expanded vLVs on spinal cord demyelinating lesions
(Supplementary Fig. 7a). LPC injection induced an increase in
the number of F4/80+ microglia and monocyte-derived macro-
phages, Iba1+ microglia, and CD3+ T cells in the injected side
compared with the contralateral side (Supplementary Fig. 7b–d).
AAV-control had no effect on immune-cell numbers, while the
numbers of F4/80+, Iba1+, and CD3+ cells were further ampliﬁed
in LPCVEGF-C mice (Supplementary Fig. 7b–d). LPCVEGF-C trap
mice showed signiﬁcantly reduced leukocyte numbers when
compared to LPCVEGF-C mice, however, leukocyte inﬁltration
was not reduced when compared to untreated LPCcontrol mice
(Supplementary Fig. 7b–d). Inﬂitration of F4/80+ macrophages/
microglia and CD3+ T cells was also not signiﬁcantly different
between K14 homozygous and heterzozygous LPC-injured mice
(Supplementary Fig. 7e, f). Altogether, these results demonstrate
that a gain-of-vLVs ampliﬁed the cytotoxic effect resulting from
LPC-induced injury.
Discussion
We here report the 3D anatomy and the function of vLVs in the
vertebral canal (Fig. 5f). The data reveal an extensive and complex
lymphatic vasculature in the vertebral column, surprisingly dense
in comparison to the one that covers the cranial dura mater15.
Previous literature reported the presence of LVs on whole-mount
preparations of vertebral dura mater in monkeys34 and on sec-
tions of intact and injured vertebral tissue in humans35. Pioneer
studies in the late 19th and early 20th centuries36–38 and later
works of Ivanow19 and Brierley and Fields20 had investigated the
ﬂow of the lymph stream along the spine and in the spinal roots
of the cord, providing evidence that lymphatics contribute to the
propagation of infectious agents (toxins, polyomyelitis, tetanus)39.
More recently, a continuum of metameric spinal lymphatics was
described in the cervical, thoracic and lumbar areas of the ver-
tebral column, both on dorsal and ventral sides, with lateral exits
of the vertebral canal along blood vessels and spinal nerves14. We
here extend these seminal ﬁndings by 3D-views of lymphatic
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vasculature organization and function in vertebral canal drainage
(Fig. 6g).
Each vertebra is drained by semicircular dorsal and ventral
vessels, which exit the vertebral column at intervertebral for-
amina. vLVs extend along spinal nerve rami to reach lymph
nodes adjacent to the cervical, thoracic and lumbar regions of the
spine, as well as the thoracic lymphatic duct in the thoracic
region. The vertebral lymphatic network is thus organized as a
metameric network of peripheral LV-connected vertebral lym-
phatic units that are interconnected by a few thin longitudinal
vessels. The absence of large longitudinal dorsal or ventral LVs
suggests that vLVs do not drain vertebral lymph as a continuous
stream along the vertebral column axis, but rather at the level of
each vertebra. This model is supported by our ﬁndings that
vertebral lymphatic vasculature consists mainly of an extensive
network of epidural vessels, located in the intervertebral tissue
and beneath the ligamentum ﬂavum, and which drain the epi-
dural lymph of the vertebral column. These observations do not
exclude that the spinal CSF may also follow a directional down-
ward ﬂux within the central canal and the spinal subarachnoid
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space, toward the caudal end of the spine, as recently demon-
strated by dynamic in vivo imaging of CSF ﬂow after intraven-
tricular CSF tracer injection40. In line with our observations, the
authors report the outﬂow of CSF tracers from the spinal sub-
arachnoid space from intravertebral regions of the sacral spine
toward sacral and iliac LNs.
Interestingly, consistently with our earlier previous ﬁndings14,
we found vLVs in contact with dura mater (Supplementary
Fig. 4c, f), where molecular tracers were also detected within
vLVs, around DRGs and spinal nerve rami (Fig. 6b–e). Sub-
sequent surgeries speciﬁcally delivering ﬂuorescent tracers within
the spinal cord subarachnoid space will be required to determine
whether these vertebral dural vLVs may be hotspots contributing
to CSF uptake toward lumbo-sacral LNs.
We note that there is a regional variation in the LV size, which
is inversely correlated to the volume of CSF, with large cerebral
ventricular volumes associated with a discrete network of cranial
mLVs and a small vertebral ependymal volume correlated with a
large vertebral lymphatic vasculature. One possible explanation is
that vertebral LVs strongly contribute to the reuptake of the CSF
that is continuously produced by the ventricular choroid plexus
and circulates in the ependymal canal of the spinal cord8. This
model is supported by the presence of dura mater vLVs in the
spine and their dense location around spinal nerve rami. A sec-
ond and likely possibility is that the largest part of vLVs uptakes
epidural ﬂuids and cells. This assumption is supported by the
presence of a large network of epidural vessels that extends from
the peripheral lymphatic system (Fig. 5e, f) and drains the ver-
tebral canal toward lymph nodes adjacent to the spinal cord
(Fig. 6f, g).
Vertebral LVs localize mainly at the level of intervertebral
ligaments or joints, much like cranial lymphatics that navigate in
skull commissures alongside blood vasculature and spinal
nerves14. We and others ﬁnd that LVs avoid bone tissues41,42.
Interestingly, the presence of LVs inside bone is observed in
patients with vanishing bone disease (also called Gorham Stout
disease GSD)43. GSD is a sporadic disease characterized by the
presence of lymphatic vessels in bone and progressive bone loss.
GSD can affect any bone in the body, but it most frequently
affects the ribs and vertebrae, with poor prognosis44,45.
Mechanisms preventing LV formation in bone are, however,
currently unknown.
In contrast to skull sutures between skull cap bones, which are
few, narrow and ﬁxed, the vertebral disks, joints and ligaments
between vertebral bones are numerous, large and mobile. They
sustain the integrity and ﬂexibility of the spine, which is predicted
to require extensive interstitial ﬂuid drainage. The large network
of epidural vLV appears to be exquisitely adapted to this extensive
drainage of non-neural peripheral tissues in the spine and to
provide each vertebra with its proper clearance system toward
collecting lymph node (Fig. 6g). It is predictable that defective
vLVs will alter vertebral and intervertebral tissue maintenance,
leading to spine orthopedic pathologies.
The proximity of two distinct epidural and dura mater vLV
circuits raises questions about the privileged immune status of the
CNS. Like in the skull13, a proximity between vLVs and CD45+
leukocytes is observed along the spine (Fig. 8). The spinal cord
lymphatic vasculature thus appears as a potentially important
immune surveillance interface between the CNS and peripheral
tissues. The cervical, thoracic and lumbar regions directly drain
into cervical, mediastinal and renal/lumbar lymph nodes,
respectively, which suggests that the peri-lymphatic dendritic
immune cells may transfer to those lymph nodes and initiate
lymphocyte activation against speciﬁc pathogens or antigens. On
the other hand, epidural and dura mater vLV may facilitate the
propagation of peripheral infections through the vertebral canal
toward neural tissues. For example, epidural vLVs may provide
entry for meningitis infection into spinal meninges. The contact
zone between DRGs and vLVs appears as another potential gate
for entry into the CNS for pathogens. For example, bovine scrapie
protein is ﬁrst detected in the mesenteric lymph nodes and DRGs
of lemurs or cattles infected orally with the agent of bovine
spongiform encephalopathy (BSE)46,47.
The spine is affected by variety of diseases including infec-
tions47, acute spinal cord compressions48, and degenerative spine
disorders, a common condition in the ageing Western popula-
tion49. Vertebral LVs are potential targets for these pathologies.
The vertebral column is also a common site for skeletal metas-
tastic tumors; as many as 70% of cancer patients have spinal
metastases, and up to 10% of cancer patients develop metastatic
cord compression50. Since lymphatics may serve as conduits for
primary tumor cells in metastatic spreading51, speciﬁc inter-
ference with the vertebral lymphatic vasculature could reduce or
prevent spinal metastasis. Alternatively, lymphatic vessels are the
ﬁrst barrier for initiation of an adaptive immune response by
antigen-presenting cells52. Facilitating the entry of immune cells
into vLVs might thus also potentially improve the efﬁciency of
immune checkpoint inhibitor treatments to destroy spinal
tumor cells.
We found that adult vLVs rapidly expand in response to
VEGF-C or tissue injury (Fig. 7c, f, i). In inﬂammatory conditions
such as LPC-induced spinal cord demyelination, VEGF-C-pre-
treatment resulted in a strong expansion of vLV circuits and the
epidural immune-cell pool. These extra-parenchymal lympho-
immune responses were associated with larger demyelinated
lesions and increased number of peri-lesional neuronal cells in
the parenchyme compared to LPCcontrol mice (Fig. 8g, h and
Supplementary Fig. 7a). In this setting, the expansion of vLV
coverage therefore exacerbated the cytotoxic inﬂammation and
impaired the recovery of local tissue damage. In contrast to the
beneﬁcial effect of loss of skull meningeal lymphatics in EAE
mice17, LPCVegf-C trap and LPC-K14-VEGFR3-Ig mice failed to
Fig. 7 vLVs are VEGF-C dependent and remodel after spinal injury. a–f VEGF-C induces epidural and dural lymphangiogenesis. a–c Cervical spine
lymphangiogenesis after i.c.m. injection of AAV-mVEGF-C. a Schematic of i.c.m. injection to deliver AAVs into the CSF and toward the cervical spine.
b, c LSFM coronal view of the cervical spine one month after AAV injection. Pattern of PROX1+ LVs (white) in AAV-control (b) and AAV-mVEGF-C (c)
mice. Note that VEGF-C induced a robust epidural and dural lymphangiogenesis. d–f Thoraco-lumbar lymphangiogenesis induced by lumbo-sacral delivery
of AAV-mVEGF-C. d Schematic of AAV injection sites into the lumbo-sacral spinal cord, adapted from Fig. 2c in ref. 59. e, f Pattern of PROX1+ LVs (white)
in AAV-control (e) and AAV-mVEGF-C (f) mice. White asterisk: vertebral ventral body; SC: Spinal cord. g–i Focal injury in the thoraco-lumbar spinal cord.
g Schematic of LPC injection into the thoraco-lumbar spinal cord, adapted from Fig. 2c in ref. 59. h, i Pattern of PROX1+ LVs (white) in control-non lesioned
(h) and LPC-injected mice (i). Inset in (i) shows the spinal cord lesion (stippled area), spatial orientation (D: dorsal, L: lateral, V: ventral). j, k Quantiﬁcation
of lymphatic vessel diameter (red stippled area in (i)) after LPC-spinal cord injury in gain- and loss-of-mVEGF-C signaling mice (j) and in LPC-injured K14-
VEGFR3-Ighom mice and -K14-VEGFR3-Ighet (control) mice (k). n= 4 biologically independent mice/independent experiment, and data show mean+/−SD
(error bar) in (j, k); one-way ANOVA with Tukey’s multiple-comparisons test (j) and Mann–Whitney U test (k); *p < 0.05, ***p < 0.001. Source data are
provided as a Source Data ﬁle. Scale bars: 300 µm (b, c, e, f, h, i)
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show signiﬁcantly reduced immune-cell inﬂitration and demye-
lination resulting from vLV blockade. This may be due to alter-
native growth factors, incomplete vLV deletion, or simply harder
to detect in a context of lower levels of inﬂammation in LPC-
treated mice compared with EAE mice.
Vertebral LVs never contact the spinal cord tissue, even upon
VEGF-C overexpression or acute spine lesion. In contrast, vLVs
are closely apposed around the chains of sensory and sympathetic
nervous ganglia. Although no lymphatic vascularization of sym-
pathetic ganglia was observed, lymphatic vessels may provide
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molecular signals to the sympathetic neurons that control vas-
cular tone of lymphatic ducts and cerebral arteries and arterioles.
Previous observations also showed that adrenergic ﬁbers connect
to the thoracic lymphatic duct and also innervate the wall of
lymph node arterioles53,54. The crosstalk between spine LVs and
the sympathetic system is thus likely relevant for the regulation of
peripheral lymph and glymphatic drainage and may coordinate
them with the activity of brain and spine tissues. We speculate
that a regulatory loop may link meningeal LV, sympathetic chain
neurons and both CNS and peripheral ﬂuid drainage.
To conclude, this study shows that the volume imaging tech-
nique allows the description of neurovascular systems by pre-
serving the anatomy and the 3D-continuity of vascular and neural
structures. In particular, our studies characterize the 3D-
anatomical organization, the remodeling and function of the
lymphatic vasculature along the spine. Our ﬁndings identify
vertebral LVs as an important component for the maintenance
and repair of vertebral tissues as well as a gatekeeper of CNS
immunity.
Methods
Study approval and mice. All in vivo procedures used in this study complied with
all relevant ethical regulations for animal testing and research, in accordance to the
European Community for experimental animal use guidelines (L358-86/609EEC).
The study received ethical approval by the Ethical Committee of INSERM (n°
2016110111126651) and the Institutional Animal Care and Use Committee of ICM
(Institut du Cerveau et de la Moelle épinière). Male C57BL/6J mice, Vegfr3:YFP
lymphatic reporter mice55, K14-VEGFR3-Ig mice31, or Prox1-eGFP mice50
between 2 and 3 months of age were used for all experiments.
Tissue preparation. Mice were given a lethal dose of Sodium Pentobarbital
(Euthasol Vet) and perfusion-ﬁxed through the left ventricle with 10 ml ice-cold
PBS then 20 ml 4% paraformaldehyde (PFA) in PBS. To dissect the spine, the skin
was completely removed, all the organs were eliminated and the ribs were removed
to keep only the vertebral column from the cervical part until the lumbar part with
the spinal cord inside. All the surrounding tissues including muscles, aorta and
ligaments were maintained around the vertebral column. The spine was cut into
pieces of about 0.5 cm (1–3 vertebrae) corresponding to the cervical, thoracic and
lumbar regions. The different spinal segments were immediately immersed in ice-
cold 4% PFA, ﬁxed overnight at +4 °C, washed in PBS, and processed for staining.
Sample pre-treatment in methanol for iDISCO+ protocol. We used a clearing
protocol developed by Renier and colleagues, which is based on methanol dehy-
dration and called the immunolabeling-enabled three-dimensional imaging of
solvent-cleared organs (iDISCO+, http://www.idisco.info)21. The steadily increas-
ing methanol concentrations result in modest tissue-shrinkage (about 10%), while
the “transparency” of tissues, such as the adult mouse brain, is increased. In detail,
ﬁxed samples were dehydrated progressively in methanol/PBS, 20, 40, 60, 80, and
100% for 1 h each (all steps were done with agitation). They were then incubated
overnight in a solution of methanol 33%/dichloromethane 66% (DCM) (Sigma
270997-12X100ML). After 2 × 1 h washes with methanol 100%, samples were
bleached with 5% H2O2 in methanol (1 vol 30% H2O2/5 vol methanol) at 4 °C
overnight. After bleaching, samples were rehydrated in methanol for 1 h each, 80%,
60%, 40%, 20%, and PBS. To clarify vertebral bone, we here added a decalciﬁcation
step using Morse solution23 during 30 min at RT. A weak acid treatment with
Morse solution (1/1 tri-sodium citrate and 45% formic acid) decalciﬁes tissues
efﬁciently while preserving their structure56–58. Samples were washed rapidly
with PBS then incubated 2 × 1 h in PTx2 (PBS/0.2% Triton X-100). At this step
they were processed for immunostaining.
Immunolabeling iDISCO+ protocol. Pretreated samples were incubated in PBS/
0.2% Triton X-100/20% DMSO/0.3 M glycine at 37 °C for 24 h, then blocked in
PBS/0.2% Triton X-100/10% DMSO/6% Donkey Serum at 37 °C for 24 h. Samples
were incubated in primary antibody dilutions in PTwH (PBS/0.2% Tween-20 with
10 mg/ml heparin)/5% DMSO/3% Donkey Serum at 37 °C for 6 days. Samples were
washed ﬁve times in PTwH until the next day, and then incubated in secondary
antibody dilutions in PTwH/3% Donkey Serum at 37 °C for 4 days. Samples were
ﬁnally washed in PTwH ﬁve times until the next day before clearing and imaging.
We used the primary antibodies listed in the Supplementary Table 1. Primary
antibodies were detected with the corresponding Alexa Fluor -555, -568, or -647
conjugated secondary antibodies from Jackson ImmunoResearch at 1/1000
dilution.
iDISCO+ tissue clearing. After immunolabeling, samples were dehydrated pro-
gressively in methanol in PBS, 20, 40, 60, 80, and 100% each for 1 h. They were
then incubated overnight in a solution of methanol 33%/DCM 66% followed by
incubation in 100% DCM for 2 × 15 min to wash the methanol. Finally, samples
were incubated in dibenzyl ether (DBE) (without shaking) until cleared (4 h) and
then stored in DBE at room temperature before imaging.
Parafﬁn section immunolabeling and imaging. Vertebrae were decalciﬁed for
3 weeks in 10% EDTA in 4% paraformaldehyde/PBS, dehydrated through ethanol,
cleared in xylene and embedded in parafﬁn. Serial cross sections (5 µm thick) were
immunostained with rabbit anti-mouse LYVE1 (1:100) polyclonal antibody (11-
034, AngioBio Co). DAB (3,3′-Diaminobenzidine) staining was performed using
the biotin avidin complex kit (PK-6100, Vectastain®Vector). Masson’s trichrome
staining was carried out using the Masson Trichrome Kit (BioGnost®- Ref. MST-
100T). Hematoxylin (5 s) was used for counter staining. HRP-labeled parafﬁn
sections were analyzed with a Zeiss Axio Scope.A1.
Cryostat section immunolabeling. For cryosections of the vertebral canal, ﬁxed
tissues underwent decalciﬁcation with 0.5 M EDTA, pH 7.4, at 4 °C. When the
bone was becoming soft, samples were washed thoroughly with PBS and immersed
in PBS containing 20% sucrose and 2% polyvinylpyrrolidone for 24 h at 4 °C,
embedded in OCT compound (Tissue-Tek), and frozen at −80 °C. In total,
50–100-μm-thick sections were cut using a cryostat (Microm HM 550/CryoStar
NX70; Thermo Fisher Scientiﬁc), air-dried, encircled with a pap pen, permeabilized
with 0.3% PBS-TX, washed with PBS, and blocked in 5% donkey serum in PBS-TX
at RT. After overnight primary antibody incubation at 4 °C in the same solution,
the sections were washed with PBS and incubated with the appropriate
ﬂuorophore-conjugated secondary antibodies diluted in 0.3% PBS-TX for 1–2 h at
RT. After washing with PBS, the sections were mounted with Vectashield
mounting medium (Vector Laboratories), sealed with Cytoseal 60, and vertebra
canal cryosections were imaged with a ﬂuorescent macroscope.
For cryosections of the spinal cord, after ﬁxation, the vertebral canal was
opened and spinal cord dissected and dehydrated in a gradient of sucrose (10, 20,
and 30% sucrose in PBS overnight for each solution at 4 °C). Then samples were
embedded in OCT compound (Tissue-Tek), and frozen for storage at −80 °C. In
total, 50–100-μm-thick sections were cut using a cryostat (Microm HM 550/
CryoStar NX70; Thermo Fisher Scientiﬁc), then blocked and permeabilized as free
ﬂoating sections in TNBT (0.1 M Tris pH 7.4; NaCl 150 mM; 0.5% blocking reagent
from Perkin Elmer; 0.5% Triton X-100) for 2 h at room temperature. Samples were
incubated in primary antibodies diluted in TNBT overnight at 4 °C, washed ﬁve
times in TNT (0.1 M Tris pH 7.4; NaCl 150 mM; 0.5% Triton X-100) and
incubated with Alexa Fluor-conjugated secondary antibodies diluted in TNBT
overnight at 4 °C. Finally, tissues were washed ﬁve times in TNT mounted in
DAKO Fluorescent Mounting Media and spinal cord cryosections were imaged
with a laser confocal microscope.
Fig. 8 Interactions of spinal LVs with immune cells. a–d Double labeling of cleared cervical vertebral column segments with antibodies against LYVE1
(green) and CD45 (purple), spatial orientation (D: dorsal, L: lateral, V: ventral). b–d Magniﬁed images of white box in (a). Merged images (a), (d) show
CD45+ leukocytes located along LYVE1+ vLVs. White asterisk: vertebral ventral body; SC: Spinal cord. e Cryosection of a cervical vertebra from a Vegfr3:
YFP mouse labeled with antibodies against MHCII (red) and CD45 (white). CD45+ leukocytes including MHCII+ antigen-presenting cells are located close
to and inside a YFP+ vLV (green) in the ligament ﬂavum. f Quantiﬁcation of CD45+ cells in vertebral column whole-mount preparations (see stippled area
in Fig. 7i). g Cryosections of the lumbar spinal cord from LPC-injured mice previously injected with AAV-VEGFR34–7-Ig (LPCcontrol), AAV-mVEGF-C
(LPCVEGF-C) or AAV-mVEGFR-31–3-Ig (LPCVEGF-C trap) in the lumbo-sacral region. Images representative of the ipsilateral side showing MBP+ myelin
(green) and demyelinated area (dashed lines) with Hoechst+ nuclear staining (blue) in (g). h Histograms showing quantiﬁcation of MBP-negative
demyelinated area (dotted line in (g)) at the lesion site. Demyelinated area is increased in LPCVEGF-C mice compared to LPCcontrol mice. n= 4 biologically
independent mice/independent experiment, and data represent mean+/−SD (error bar); one-way ANOVA with Tukey’s multiple-comparisons test; *p <
0.05, ***p < 0.001. Source data are provided as a Source Data ﬁle. Scale bars: 300 µm (a–d); 50 µm (e); 100 µm (g)
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We used the primary antibodies listed in the Supplementary Table 1. Primary
antibodies were detected with the corresponding Alexa Fluor -555, -568, or -647
conjugated secondary antibodies from Jackson ImmunoResearch at 1/1000
dilution.
Whole-mount vertebral column immunolabeling. After perfusion, lumbar seg-
ments corresponding to two adjacent vertebrae cranial and caudal to the site
of LPC injection were harvested and ﬁxed in 4% PFA overnight at 4 °C. The
vertebral canal was opened laterally to expose dorsal and ventral sides and tissues
were ﬁxed in TNBT (0.1 M Tris pH 7.4; NaCl 150 mM; 0.5% blocking reagent
from Perkin Elmer; 0.5% Triton X-100) for 2 h at room temperature before
incubation with primary antibodies diluted in TNBT overnight at 4 °C. Whole
mounts were washed ﬁve times with TNT (0.1 M Tris pH 7.4; NaCl 150 mM; 0.5%
Triton X-100) and incubated with Alexa Fluor-conjugated secondary antibodies
diluted in TNBT overnight at 4 °C. Finally, tissues were washed ﬁve times in
TNT and imaged using a Leica DMIRB epiﬂuorescence microscope using a
×4 objective.
For whole-mount staining of the larger vLV segments, ﬁxed tissues were
permeabilized with 0.3% Triton X-100 in PBS (PBS-TX) at room temperature (RT),
then blocked with 5% donkey serum/2% bovine serum albumin/0.3% PBS-TX
(DIM). Primary antibodies were diluted in DIM and samples were incubated in the
primary antibody mix at least overnight at +4 °C. After washes with PBS-TX in RT,
tissues were incubated with ﬂuorophore-conjugated secondary antibodies in PBS-
TX overnight at +4 °C, followed by washing in PBS-TX at RT. After post ﬁxation
in 1% PFA for 5 min, following washing with PBS, the stained samples were
transferred to PBS containing 0.05% NaN3 at +4 °C and imaged with a
epiﬂuorescence microscope and a ×4 objective.
We used the primary antibodies listed in the Supplementary Table 1. Primary
antibodies were detected with the corresponding Alexa Fluor -555, -568, or -647
conjugated secondary antibodies from Jackson ImmunoResearch at 1/1000
dilution.
LSFM, confocal and stereomicroscope imaging. Cleared samples were imaged in
transverse orientation with a LSFM (Ultramicroscope II, LaVision Biotec) equipped
with a sCMOS camera (Andor Neo) and a 4 × /0.3 objective lens (LVMI-Fluor 4 × /
0.3 WD6, LaVision Biotec). Version v144 of the Imspector Microscope controller
software was used. The microscope chamber was ﬁlled with DBE. We used single
sided 3-sheet illumination conﬁguration, with ﬁxed x position (no dynamic
focusing). The light sheet was generated by LED lasers (OBIS) tuned to 561 nm
100 mW and 639 nm 70mW (LVBT Laser module 2nd generation). The light-
sheet numerical aperture was set to 0.03. We used the following emission ﬁlters:
595/40 for Alexa Fluor-568 or -555, and -680/30 for Alexa Fluor-647. Stacks were
acquired using 2 μm z steps and a 30 ms exposure time per step, with a Andor
CMOS sNEO camera. The ×2 optical zoom was used for an effective magniﬁcation
of (×8), 0.8 µm/pixel. Mosaic acquisitions were done with a 10% overlap on the
full frame.
Laser scanning confocal micrographs of the ﬂuorescently labeled cryosections
were acquired using either a Zeiss Axioimager Z1 Apotome or a Leica TCS
SP8 confocal microscope (air objectives ×10 Plan-Apochromat with NA 0.45
and ×25 Plan-Apochromat with NA 1.1) with multichannel scanning in-frame.
Fluorescent stereo micrographs were obtained with AxioZoom.V16
ﬂuorescence stereo zoom microscope (Carl Zeiss) equipped with an ORCA-Flash
4.0 digital sCMOS camera (Hamamatsu Photonics) or an OptiMOS sCMOS
camera (QImaging).
Image processing and analysis. For display purposes, a gamma correction of 1.47
was applied on the raw data obtained from the light-sheet ﬂuorescent microscope.
Images acquired with Imspector acquisition software in tif fomat was converted
with Imaris File Converter to IMS ﬁles. Mosaics were reconstructed with Imaris
stitcher; then Imaris software (Bitplane, http://www.bitplane.com/imaris/imaris)
was used to generate the orthogonal projections of data shown in all ﬁgures,
perform area segmentation on a stack of image slices, and apply a color code to
selected lymphatic networks.
Tracer injections. Thoracic-lumbar and lumbar-sacral spinal cord injection was
performed in adult male and female C57BL/6J mice of 8–10-week of age. Mice were
injected IP with Buprecare® solution and anaesthetized by Isoﬂurane gas (2–3%).
The skin was incised at Th12-L1 (thoracic-lumbar injection) or L6-S1 (lumbar-
sacral injection) vertebrae levels and paraspinal muscles covering the column were
moved to the side. Dura mater and arachnoid membranes were incised using 30-
gauge needle. Injections were then performed with a stereotaxic apparatus
(Stoelting). Two or eight microliters of ovalbumin (2 mg/ml) (Ovalbumin Alexa
Fluor™ 555 Conjugate (OVA-A555; O34782, Invitrogen) or LYVE1 antibody was
injected through a microcapillary (Glass Capillaries; GC120-15, Harvard Appara-
tus) connected to a Hamilton syringe. The microcapillary was introduced into one
side of the spinal cord parenchyme. To avoid the release of OVA-A555; or LYVE1
Ab during the injection, a surgical glue was added to close the incision around the
glass capillary. Injections were performed slowly (1 µl/min). Once injection was
ﬁnished, the capillary was maintained for 2 min before retraction and a surgical
glue was added to close the hole made by the capillary, however some tracer leak
always occurred despite these precautions. Tissue incisions were closed with Michel
Suture Clips (7.5 × 1.75 mm; 12040-01, Fine Science Tool). After 15 or 45 min,
mice were euthanized and perfused as described above in the “Tissue preparation”
section.
AAV injection. Adult male mice were anesthetized with isoﬂurane (induction 4%,
maintenance 2%) and placed in the stereotactic apparatus. AAVs serotype 9 were
administered by either intra-cisterna magna (i.c.m.) injection or intra-lumbo-sacral
(l.s.) injection. A single dose of 2 μl (1011 viral particles per μl) of AAV-mVEGF-C,
AAV-mVEGFR34–7-Ig or AAV-mVEGFR-31–3-Ig was administered into either
C57BL/6J or K14-VEGFR3-Ig55 male adult mice. i.c.m. and l.s. injections were
performed using a Hamilton syringe with a 34-G needle and a ﬂow rate of 0.5 μl/
min. The needle tip was retracted 2 min after the injection. Hundred microliters of
0.05 mg/kg of Buprecar® (buprenorphine) solution (intraperitoneal injection-IP)
was used to relieve pre- and post-operative pain. All AAVs were produced by the
vectorology platform of ICM.
Spinal cord focal demyelination. Adult male C57BL/6J mice were used. Lesions
were induced in the thoracic-lumbar spinal cord by a stereotaxic injection of 1%
of L-α-lysophosphatidylcholine (LPC) in PBS. Prior to the surgery, mice were
anesthetized by intraperitoneal injection of ketamine (90 mg/kg) and xylazine
(20 mg/kg) cocktail. Two longitudinal incisions into longissimus dorsi at each side
of the vertebral column were performed, and the muscle tissue covering the column
was moved to the side. Animals were placed in a stereotaxic frame, the 13th
thoracic vertebra was ﬁxed in between restraint bars designed for manipulations of
mouse spinal cord (Stoelting, Wood Dale, IL), and intravertebral space was exposed
by removing the connective tissue. The dura mater was perfored using a 30-gauge
needle, and 1 µl NaCl or LPC was injected using a glass microcapillary (Glass
Capillaries; GC120-15, Harvard Apparatus) attached via a connector to a Hamil-
ton’s syringe and mounted on a stereotaxic micromanipulator. Following injection,
muscle sheaths were sutured with 3/0 Monocryl, and the skin incision was closed
with 4/0 silk. After 7 days post injection, mice were perfused with 4% PFA in PBS;
tissues were harvested and processed for iDISCO+ protocol or whole-mount and
spinal cord stainings, as described above.
Quantiﬁcation and statistical analysis. No statistical methods were used to
predetermine sample size. Three to four mice were analyzed by experimental group
(n= 3–4 mice/group). In vivo imaging quantiﬁcation was performed with the Fiji
software (ImageJ). The investigators were blinded during experiments and outcome
assessment.
For quantiﬁcation of vLV-associated immune cells, images of coronal sections
of the cervical vertebral column labeled with immune-cell speciﬁc antibodies were
acquired with a spinning-disk confocal (Nikon Eclipse Ti) using a ×20 objective.
Cells were counted in the dorsal intervertebral spaces, in the vicinity of epidural
vLVs (n= 3–4 mice/group, 3–4 ﬁelds/mouse). The number of CD45+ leukocytes
was counted by surface unit (mm2). Myeloid cells (CD11b+), T lymphocytes
(CD3e+), B lymphocytes (CD19+), and antigen-presenting cells (MHCII+) were
counted as a percentage of CD45+ leukocytes.
For quantiﬁcation of the vertebral lymphatic vessel diameter and area, images of
whole-mount thoraco-lumbar vertebral canals stained with anti-LYVE1 antibody
were acquired with a Leica DMIRB inverted epiﬂuorescence microscope using a ×4
objective. The entire intervertebral space was quantiﬁed for each mice, and between
10 and 30 vessels were counted by mouse, depending on experimental conditions
(n= 4 mice/group).
For quantiﬁcation of demyelinated area, pictures of MBP-labeled tissues were
acquired in the white mater, at the level of the LPC injection (n= 4 mice/group, 2
ﬁelds/mouse). Demyelinated areas were measured as surfaces of pixel intensity
under 50 (scale 0–255).
For quantiﬁcation of vLV-associated immune cells in mice with a
demyelinating lesion, coronal sections of the cervical vertebral column were
labeled with immune-cell speciﬁc antibodies and images were acquired with a
Leica SP8 confocal using a ×25 objective. Cells were counted in the center of the
demyelinated lesion and in the contralateral side of the spinal cord (n= 4 mice/
group, 2 ﬁelds/mouse).
Statistical data analysis was performed with the Prism 6.0 software (GraphPad).
For continuous variables (area, diameter), data are presented as mean ± standard
deviation (SD). For discrete variables (immune-cell number), data are presented as
mean standard error of the mean (SEM). A two-tailed, unpaired Student’s t test or
Mann–Whitney U test was done to determine statistical signiﬁcance between two
groups. For comparison between more than two groups, the one-way ANOVA test
was performed, followed by Turkey’s multiple comparison test. Differences were
considered statistically signiﬁcant if the p value was <0.05 (*p < 0.05, **p < 0.01,
***p < 0.005, and ****p < 0.0001).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
The source data underlying Fig. 7j, k and 8f–h as well as Supplementary Figs. 6b, d–f and
7a–f are provided as a Source Data ﬁle. All data supporting the ﬁndings of this study are
available from the corresponding authors upon reasonable request.
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